• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

纳武利尤单抗联合伊匹木单抗与化疗用于转移性非小细胞肺癌：综述及一例PD-L1阴性患者的病例研究

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1.

作者信息

Morabito Alessandro

机构信息

Oncologia Clinica Sperimentale Toraco-Polmonare, Istituto Nazionale dei Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.

出版信息

Drugs Context. 2024 Jul 19;13. doi: 10.7573/dic.2024-5-3. eCollection 2024.

DOI:10.7573/dic.2024-5-3
PMID:39072302
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11281098/
Abstract

The advent of immunotherapy, and in particular the use of immune-checkpoint inhibitors, has profoundly revolutionized the treatment of different cancers, including lung cancer. The use of immune-checkpoint inhibitors has prolonged survival in lung cancer with a strong benefit in a significant percentage of patients with non-small-cell lung cancer. Here, a clinical case of a patient who, despite testing negative for PD-L1, displayed a sustained complete response to immunotherapy treatment in advanced metastatic non-small-cell lung cancer is presented. Additionally, recent findings concerning the application of immunotherapy in this context are reviewed.

摘要

免疫疗法的出现，尤其是免疫检查点抑制剂的使用，已经深刻地革新了包括肺癌在内的不同癌症的治疗方法。免疫检查点抑制剂的使用延长了肺癌患者的生存期，对相当比例的非小细胞肺癌患者有显著益处。在此，介绍一例晚期转移性非小细胞肺癌患者的临床病例，该患者尽管PD-L1检测呈阴性，但对免疫治疗仍表现出持续的完全缓解。此外，还综述了在这种情况下免疫疗法应用的最新研究结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ef/11281098/5f8bed71edd3/DIC-2024-5-3_MORABITO_TS_080724-Figure_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ef/11281098/7b0fd93312ec/DIC-2024-5-3_MORABITO_TS_080724-Figure_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ef/11281098/b43cb7903438/DIC-2024-5-3_MORABITO_TS_080724-Figure_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ef/11281098/5f8bed71edd3/DIC-2024-5-3_MORABITO_TS_080724-Figure_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ef/11281098/7b0fd93312ec/DIC-2024-5-3_MORABITO_TS_080724-Figure_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ef/11281098/b43cb7903438/DIC-2024-5-3_MORABITO_TS_080724-Figure_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ef/11281098/5f8bed71edd3/DIC-2024-5-3_MORABITO_TS_080724-Figure_3.jpg

相似文献

1
Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1.纳武利尤单抗联合伊匹木单抗与化疗用于转移性非小细胞肺癌：综述及一例PD-L1阴性患者的病例研究
Drugs Context. 2024 Jul 19;13. doi: 10.7573/dic.2024-5-3. eCollection 2024.
2
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.纳武利尤单抗联合伊匹木单抗一线治疗晚期 NSCLC：CheckMate 227 部分 1 期随机、开放标签、3 期临床试验的 4 年结果。
J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12.
3
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.CheckMate 9LA 随机试验中，一线纳武利尤单抗联合伊匹单抗加化疗治疗转移性非小细胞肺癌的 4 年临床更新和治疗转换调整结局。
J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189.
4
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.CheckMate 227 研究第一部分：转移性非小细胞肺癌一线纳武利尤单抗联合伊匹木单抗治疗：日本患者 5 年结果
Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7.
5
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis.免疫检查点抑制剂作为非小细胞肺癌一线治疗：系统评价和荟萃分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2169531. doi: 10.1080/21645515.2023.2169531. Epub 2023 Jan 30.
6
Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.纳武利尤单抗联合伊匹单抗用于转移性非小细胞肺癌的一线治疗。
Expert Rev Anticancer Ther. 2021 Jul;21(7):705-713. doi: 10.1080/14737140.2021.1903322. Epub 2021 Mar 28.
7
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
8
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.纳武利尤单抗联合伊匹单抗对比化疗作为一线治疗用于 CheckMate 227 研究转移性非小细胞肺癌的 5 年生存结果。
J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12.
9
Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies.纳武利尤单抗联合伊匹木单抗对既往接受过抗程序性死亡蛋白-1和/或抗程序性死亡配体-1抗体治疗的晚期非小细胞肺癌患者进行再免疫治疗。
Discov Oncol. 2023 Aug 31;14(1):163. doi: 10.1007/s12672-023-00781-5.
10
Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.缺乏驱动基因突变的晚期非小细胞肺癌一线PD-1/PD-L1抑制剂的疗效比较：系统评价和贝叶斯网络荟萃分析
Ther Adv Chronic Dis. 2023 Oct 11;14:20406223231189224. doi: 10.1177/20406223231189224. eCollection 2023.

本文引用的文献

1
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.用于预测肿瘤免疫检查点抑制剂疗效的生物标志物和计算模型。
Front Immunol. 2024 Mar 8;15:1368749. doi: 10.3389/fimmu.2024.1368749. eCollection 2024.
2
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.免疫检查点阻断治疗的非小细胞肺癌患者的血液生物标志物。
J Exp Clin Cancer Res. 2024 Mar 16;43(1):82. doi: 10.1186/s13046-024-02969-1.
3
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
CheckMate 9LA 随机试验中，一线纳武利尤单抗联合伊匹单抗加化疗治疗转移性非小细胞肺癌的 4 年临床更新和治疗转换调整结局。
J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189.
4
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1.伴有驱动基因改变的 IV 期非小细胞肺癌的治疗：ASCO 临床实践指南，2023.1 版。
J Clin Oncol. 2023 May 20;41(15):e42-e50. doi: 10.1200/JCO.23.00281. Epub 2023 Apr 6.
5
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。
J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.
6
The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials.免疫检查点抑制剂在罕见肿瘤中的疗效：已发表临床试验的系统评价。
Crit Rev Oncol Hematol. 2022 Jun;174:103700. doi: 10.1016/j.critrevonc.2022.103700. Epub 2022 May 6.
7
First-Line Immunotherapy for Non-Small-Cell Lung Cancer.非小细胞肺癌的一线免疫治疗。
J Clin Oncol. 2022 Feb 20;40(6):586-597. doi: 10.1200/JCO.21.01497. Epub 2022 Jan 5.
8
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.STK11 和 KEAP1 突变型肺腺癌中程序性死亡受体-(配体)1 抑制作用降低受 KRAS 突变状态影响。
J Thorac Oncol. 2022 Mar;17(3):399-410. doi: 10.1016/j.jtho.2021.10.013. Epub 2021 Nov 2.
9
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.纳武利尤单抗联合伊匹木单抗一线治疗晚期 NSCLC：CheckMate 227 部分 1 期随机、开放标签、3 期临床试验的 4 年结果。
J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12.
10
Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review.免疫检查点抑制剂在罕见肿瘤中的疗效：系统评价。
Front Immunol. 2021 Sep 20;12:720748. doi: 10.3389/fimmu.2021.720748. eCollection 2021.